WuXi Biologics bets on China's MAH scheme with new facility

Chinese biologics services provider WuXi Biologics (HK: 2269) recently started the operation of a new current Good Manufacturing Practices (cGMP) facility for biologics manufacturing in Wuxi, Jiangsu province, writes Wang Fangqing, The Pharma Letter’s local correspondent.

Boasting the world’s largest biologics cGMP using disposable bioreactors, the $150 million facility is equipped with 2 x1000L perfusion bioreactors and 14 x 2000L fed-batch culture reactors, all supplied by the US companies Thermo Fisher and GE.

According to WuXi Bio, the facility, which can produce a variety of bio therapies, including recombinant proteins and antibodies, will supply clinical studies and commercial use as well.